Developer docs
API playgroundTry for free, no card

Search company profiles

Drake Rayden Foundation

Full company profile

uuid00snip2

Namestring
Drake Rayden Foundation
Legal namestring
Drake Rayden Foundation
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Drake Rayden Foundation is a 501(c)(3) nonprofit organization (EIN 82-2383660) founded in 2016 by Eric and Tarah O'Sullivan in Simpsonville, South Carolina, after their son Drake was diagnosed with Nonketotic Hyperglycinemia (NKH), an extremely rare metabolic disorder in which approximately 85% of severe cases result in a prognosis measured in days or weeks. The foundation's core mission is to fund and accelerate the development of curative treatments for NKH, with the central technical initiative being an AAV-based gene replacement therapy co-developed since 2019 with the Steven Gray Lab at the University of Texas Southwestern and now advancing toward a 2026 clinical trial, with clinical-grade AAV manufacturing partnered to Andelyn Biosciences. Complementary research tracks include cinnamon-based treatment derivatives prompted by Drake's documented response, which has since engaged three independent research facilities.

The foundation operates a faith-based, community-led model in which revenue is generated entirely through tax-deductible donations, grassroots fundraising campaigns, and events such as the annual HEISENOUGH Event in Spartanburg, SC, rather than through the sale of products or services. Its go-to-market relies on a content-and-narrative engine: an extensive blog (Life with NKH, Research Updates, Give Me Jesus), active social media presence across YouTube, Instagram, Facebook, Twitter/X, LinkedIn, and Pinterest, email newsletters, and a documentary film project (He Is Enough Film). Beneficiary segments are families affected by NKH (primary) and the broader special-needs and faith-based supporter community (secondary); the foundation also functions as a connector between NKH families and researchers. Operational scale is small — described as primarily founder-operated with volunteer support — and the foundation reports no institutional investors, parent company, or commercial revenue streams.

Short descriptiontext

Drake Rayden Foundation is a 501(c)(3) nonprofit funding AAV-based gene therapy research for Nonketotic Hyperglycinemia through partnerships with the Steven Gray Lab at UTSW and Andelyn Biosciences, supporting affected families via donations, events, and community-led awareness.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSimpsonville, United States
HQ citystring
Simpsonville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease research, patient advocacy services, nonprofit fundraising events, gene therapy funding, special needs support
Industry3 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking Foundations813211
SIC code1 code
  • Services-Social Services8300
Product category
Rare Disease Patient Advocacy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations
TypeAffiliate Referral
Description

501(c)(3) nonprofit organization accepting tax-deductible donations through PayPal and other channels to fund NKH research and family support programs.

drakeraydenfoundation.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Drake Rayden Foundation is a 501(c)(3) nonprofit organization that funds research and builds partnerships to develop treatments for Nonketotic Hyperglycinemia (NKH), a terminal rare metabolic disorder. The foundation supports a gene replacement therapy research program with the Steven Gray Lab at UTSW, raises awareness and donations through events like HEISENOUGH, and provides community resources for NKH families.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Founded gene therapy research partnership that has progressed to planned 2026 clinical trial
+1 more record
Product overview1 text field

Drake Rayden Foundation is a 501(c)(3) non-profit organization focused on raising awareness and funds for Non-Ketotic Hyperglycinemia (NKH) research, providing care for special needs families, and bringing hope through the gospel. The foundation primarily operates through advocacy, fundraising events (such as the HEISENOUGH Event), and partnering with research institutions like the Steven Gray Lab at University of Texas Southwestern for gene therapy development. Their core activities include gene therapy research for NKH treatment, family support resources, and community awareness campaigns.

Product and service5 records
1NKH Gene Therapy Research
CategoryResearch Program
Description

Research initiative partnering with the Steven Gray Lab at University of Texas Southwestern to develop gene replacement therapy for Nonketotic Hyperglycinemia, a terminal rare disease.

2HEISENOUGH Event
CategoryFundraising Event
Description

Annual fundraising and awareness event hosted in Spartanburg, SC featuring worship, presentations, and community gathering to support NKH gene therapy research.

3NKH Family Support Resources
CategoryFamily Support
Description

Blog posts, research updates, and informational resources for families affected by Nonketotic Hyperglycinemia including life updates, medical information, and community connection opportunities.

4He Is Enough Film
CategoryDocumentary Content
Description

Documentary film project telling the story of the Drake Rayden Foundation's journey with NKH and faith.

5DRF Open / Drake Rayden Cup
CategoryFundraising Event
Description

Fundraising events and initiatives to support NKH research and family care programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1University of Texas Southwestern - Steven Gray Lab
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Two-year partnership initiated in 2019 to create a gene replacement therapy for Non-Ketotic Hyperglycinemia. The foundation partnered with Dr. Steven Gray's lab at UTSW to develop AAV-based gene therapy for this terminal rare disease. This partnership is central to the foundation's mission to find a cure.

drakeraydenfoundation.com
2Andelyn Biosciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Andelyn Biosciences will apply the AAV Curator platform to manufacture clinical-grade AAV for the Drake Rayden Foundation for the treatment of Non-Ketotic Hyperglycinemia. This partnership is for manufacturing the gene therapy for clinical trials.

drakeraydenfoundation.com
3Medical University of South Carolina (MUSC)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MUSH colleague helped host the SCRDAC Rare Disease Symposium. Tarah O'Sullivan was invited to speak at this rare disease conference hosted in part by MUSC.

drakeraydenfoundation.com
4NKH Families and Researchers
Strategic tierCoreTypeOthers
Description

Foundation connects NKH families with researchers, shares treatment discoveries (like cinnamon protocol), and facilitates research collaboration across multiple facilities.

drakeraydenfoundation.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Cystic Fibrosis Foundation
TypeBroad incumbent
Description

The largest US disease-specific research grantmaking foundation, funding a robust therapeutic pipeline for a single rare disease. Directly comparable as a rare-disease grantmaking model that has historically driven gene and modality therapy development from academic labs to clinic.

2Parent Project Muscular Dystrophy
TypeDirect peer
Description

Disease-specific nonprofit funding Duchenne muscular dystrophy research, including gene therapy programs. Highly comparable in mission, structure (parent-founded), and gene therapy grantmaking focus.

3Cure SMA
TypeDirect peer
Description

Spinal muscular atrophy patient organization that helped fund the development of Spinraza and Zolgensma. Directly comparable as a parent-driven rare disease foundation that converted small-scale fundraising into clinical-stage gene therapy assets.

4National Organization for Rare Disorders (NORD)
TypeBroad incumbent
Description

Umbrella advocacy and research organization for all rare diseases in the US. Comparable as the broader ecosystem hub in which disease-specific foundations like Drake Rayden operate and through which they amplify voice.

5Foundation for Angelman Syndrome Therapeutics (FAST)
TypeDirect peer
Description

Parent-founded rare disease nonprofit actively funding AAV-based gene therapy for Angelman Syndrome. Comparable in being a small, family-driven foundation co-funding academic gene therapy programs toward clinical trials.

6CureDuchenne
TypeDirect peer
Description

Disease-specific nonprofit funding exon-skipping and gene therapy approaches for Duchenne. Comparable in mission, scale envelope, and emphasis on catalyzing academic-to-clinical gene therapy pipelines.

7EveryLife Foundation for Rare Diseases
TypeBroad incumbent
Description

Public policy advocacy foundation serving the broader rare disease community. Comparable as a peer nonprofit operating in the same regulatory and funding advocacy ecosystem.

8A Foundation Building Strength
TypeDirect peer
Description

Parent-founded nonprofit funding gene therapy research for Nemaline Myopathy, another ultra-rare genetic disorder. Comparable in family-led origin, small operational footprint, and academic gene therapy grantmaking model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Drake Rayden Foundation

Rare Disease Patient Advocacydrakeraydenfoundation.com

Drake Rayden Foundation is a 501(c)(3) nonprofit funding AAV-based gene therapy research for Nonketotic Hyperglycinemia through partnerships with the Steven Gray Lab at UTSW and Andelyn Biosciences, supporting affected families via donations, events, and community-led awareness.

What Drake Rayden Foundation does

Drake Rayden Foundation is a 501(c)(3) nonprofit organization (EIN 82-2383660) founded in 2016 by Eric and Tarah O'Sullivan in Simpsonville, South Carolina, after their son Drake was diagnosed with Nonketotic Hyperglycinemia (NKH), an extremely rare metabolic disorder in which approximately 85% of severe cases result in a prognosis measured in days or weeks. The foundation's core mission is to fund and accelerate the development of curative treatments for NKH, with the central technical initiative being an AAV-based gene replacement therapy co-developed since 2019 with the Steven Gray Lab at the University of Texas Southwestern and now advancing toward a 2026 clinical trial, with clinical-grade AAV manufacturing partnered to Andelyn Biosciences. Complementary research tracks include cinnamon-based treatment derivatives prompted by Drake's documented response, which has since engaged three independent research facilities.

The foundation operates a faith-based, community-led model in which revenue is generated entirely through tax-deductible donations, grassroots fundraising campaigns, and events such as the annual HEISENOUGH Event in Spartanburg, SC, rather than through the sale of products or services. Its go-to-market relies on a content-and-narrative engine: an extensive blog (Life with NKH, Research Updates, Give Me Jesus), active social media presence across YouTube, Instagram, Facebook, Twitter/X, LinkedIn, and Pinterest, email newsletters, and a documentary film project (He Is Enough Film). Beneficiary segments are families affected by NKH (primary) and the broader special-needs and faith-based supporter community (secondary); the foundation also functions as a connector between NKH families and researchers. Operational scale is small — described as primarily founder-operated with volunteer support — and the foundation reports no institutional investors, parent company, or commercial revenue streams.

Drake Rayden Foundation firmographics

Firmographics
Name
Drake Rayden Foundation
Legal name
Drake Rayden Foundation
Website
https://drakeraydenfoundation.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Drake Rayden Foundation is a 501(c)(3) nonprofit funding AAV-based gene therapy research for Nonketotic Hyperglycinemia through partnerships with the Steven Gray Lab at UTSW and Andelyn Biosciences, supporting affected families via donations, events, and community-led awareness.
Ownership category
akta.pro rank

Drake Rayden Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking Foundations (813211)
SIC
Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease research
  • Patient advocacy services
  • Nonprofit fundraising events
  • Gene therapy funding
  • Special needs support

Where Drake Rayden Foundation is headquartered

Location

Headquarters

HQ city
Simpsonville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Drake Rayden Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. Donations: 501(c)(3) nonprofit organization accepting tax-deductible donations through PayPal and other channels to fund NKH research and family support programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Drake Rayden Foundation product offering

Product offering

Core offering

Drake Rayden Foundation is a 501(c)(3) nonprofit organization that funds research and builds partnerships to develop treatments for Nonketotic Hyperglycinemia (NKH), a terminal rare metabolic disorder. The foundation supports a gene replacement therapy research program with the Steven Gray Lab at UTSW, raises awareness and donations through events like HEISENOUGH, and provides community resources for NKH families.

Product overview

Drake Rayden Foundation is a 501(c)(3) non-profit organization focused on raising awareness and funds for Non-Ketotic Hyperglycinemia (NKH) research, providing care for special needs families, and bringing hope through the gospel. The foundation primarily operates through advocacy, fundraising events (such as the HEISENOUGH Event), and partnering with research institutions like the Steven Gray Lab at University of Texas Southwestern for gene therapy development. Their core activities include gene therapy research for NKH treatment, family support resources, and community awareness campaigns.

Differentiator

Problem solved

Functional benefit

Products and services

  • NKH Gene Therapy Research Research initiative partnering with the Steven Gray Lab at University of Texas Southwestern to develop gene replacement therapy for Nonketotic Hyperglycinemia, a terminal rare disease.
  • HEISENOUGH Event Annual fundraising and awareness event hosted in Spartanburg, SC featuring worship, presentations, and community gathering to support NKH gene therapy research.
  • NKH Family Support Resources Blog posts, research updates, and informational resources for families affected by Nonketotic Hyperglycinemia including life updates, medical information, and community connection opportunities.
  • He Is Enough Film Documentary film project telling the story of the Drake Rayden Foundation's journey with NKH and faith.
  • DRF Open / Drake Rayden Cup Fundraising events and initiatives to support NKH research and family care programs.

Quantifiable outcome

  • Founded gene therapy research partnership that has progressed to planned 2026 clinical trial
  • +1 more outcomes

Companies that use Drake Rayden Foundation

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Drake Rayden Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Drake Rayden Foundation partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • University of Texas Southwestern - Steven Gray LabcoreStrategic or Co-development Partner · 1 January 2019Two-year partnership initiated in 2019 to create a gene replacement therapy for Non-Ketotic Hyperglycinemia. The foundation partnered with Dr. Steven Gray's lab at UTSW to develop AAV-based gene therapy for this terminal rare disease. This partnership is central to the foundation's mission to find a cure.
  • Andelyn BiosciencescoreStrategic or Co-development PartnerAndelyn Biosciences will apply the AAV Curator platform to manufacture clinical-grade AAV for the Drake Rayden Foundation for the treatment of Non-Ketotic Hyperglycinemia. This partnership is for manufacturing the gene therapy for clinical trials.
  • Medical University of South Carolina (MUSC)minorStrategic or Co-development PartnerMUSH colleague helped host the SCRDAC Rare Disease Symposium. Tarah O'Sullivan was invited to speak at this rare disease conference hosted in part by MUSC.
  • NKH Families and ResearcherscoreOthersFoundation connects NKH families with researchers, shares treatment discoveries (like cinnamon protocol), and facilitates research collaboration across multiple facilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Drake Rayden Foundation competitors and assessment

Company assessment

Broad incumbents

  • Cystic Fibrosis Foundation: The largest US disease-specific research grantmaking foundation, funding a robust therapeutic pipeline for a single rare disease. Directly comparable as a rare-disease grantmaking model that has historically driven gene and modality therapy development from academic labs to clinic.
  • National Organization for Rare Disorders (NORD): Umbrella advocacy and research organization for all rare diseases in the US. Comparable as the broader ecosystem hub in which disease-specific foundations like Drake Rayden operate and through which they amplify voice.
  • EveryLife Foundation for Rare Diseases: Public policy advocacy foundation serving the broader rare disease community. Comparable as a peer nonprofit operating in the same regulatory and funding advocacy ecosystem.

Direct peers

  • Parent Project Muscular Dystrophy: Disease-specific nonprofit funding Duchenne muscular dystrophy research, including gene therapy programs. Highly comparable in mission, structure (parent-founded), and gene therapy grantmaking focus.
  • Cure SMA: Spinal muscular atrophy patient organization that helped fund the development of Spinraza and Zolgensma. Directly comparable as a parent-driven rare disease foundation that converted small-scale fundraising into clinical-stage gene therapy assets.
  • Foundation for Angelman Syndrome Therapeutics (FAST): Parent-founded rare disease nonprofit actively funding AAV-based gene therapy for Angelman Syndrome. Comparable in being a small, family-driven foundation co-funding academic gene therapy programs toward clinical trials.
  • CureDuchenne: Disease-specific nonprofit funding exon-skipping and gene therapy approaches for Duchenne. Comparable in mission, scale envelope, and emphasis on catalyzing academic-to-clinical gene therapy pipelines.
  • A Foundation Building Strength: Parent-founded nonprofit funding gene therapy research for Nemaline Myopathy, another ultra-rare genetic disorder. Comparable in family-led origin, small operational footprint, and academic gene therapy grantmaking model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Drake Rayden Foundation social profiles

Digital presence

Drake Rayden Foundation compliance and trust

Trust signal

Compliance1 record

Drake Rayden Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Drake Rayden Foundation leadership team

Management profile

Number of profiles

Profiles2 records

Drake Rayden Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Drake Rayden Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drake Rayden Foundation

What does Drake Rayden Foundation do?

Drake Rayden Foundation is a 501(c)(3) nonprofit organization that funds research and builds partnerships to develop treatments for Nonketotic Hyperglycinemia (NKH), a terminal rare metabolic disorder. The foundation supports a gene replacement therapy research program with the Steven Gray Lab at UTSW, raises awareness and donations through events like HEISENOUGH, and provides community resources for NKH families.

Is Drake Rayden Foundation a public or private company?

Drake Rayden Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Drake Rayden Foundation founded?

Drake Rayden Foundation was founded in 2017. It employs 1 to 10 people.

Where is Drake Rayden Foundation based?

Drake Rayden Foundation is headquartered in Simpsonville, United States, in the North America region.

How does Drake Rayden Foundation make money?

One revenue line is on record: donations.

Who are Drake Rayden Foundation's main competitors?

Broad incumbents on record are Cystic Fibrosis Foundation, National Organization for Rare Disorders (NORD) and EveryLife Foundation for Rare Diseases. Direct peers are Parent Project Muscular Dystrophy, Cure SMA, Foundation for Angelman Syndrome Therapeutics (FAST), CureDuchenne and A Foundation Building Strength.

Does Drake Rayden Foundation have an API?

No public API is recorded for Drake Rayden Foundation.

What industry is Drake Rayden Foundation in?

Drake Rayden Foundation's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales